The deal, which involves an upfront payment of $1.75 billion, includes Xiidra, the first approved prescription treatment for the signs and symptoms of dry eye disease. Also included is investigational medicine SAF312, in development as a first-in-class therapy for chronic ocular surface pain, as well as the rights for use of the AcuStream delivery device in dry eye indications and OJL332, a second generation TRPV1 antagonist in pre-clinical development.
Per its focused strategy unveiled last year, Novartis is looking to drive R&D productivity by prioritizing high-value medicines across five core therapeutic areas — cardiovascular, immunology, neuroscience, solid tumors and hematology.
On the ophthalmology front, Novartis says it will continue its R&D efforts in addressing retinal diseases via platforms including gene therapy and optogenetics.
